LSD1-IN-13

Cat. No.:	HY-144675
CAS No.:	2170212-33-4
Molecular Formula:	$C_{23}H_{29}N_3O_2S$
Molecular Weight:	411.56
Target:	Histone Demethylase
Pathway:	Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	LSD1-IN-13 (compound 7e) is an orally active and potent LSD1 inhibitor, with an IC_{50} of 24.43 nM. LSD1-IN-13 can activate CD86 expression, with an EC_{50} of 470 nM. LSD1-IN-13 induces differentiation of AML (acute myeloid leukemia) cell lines[1].
IC_{50} & Target	IC_{50}: 24.43 ± 1.08 nM (LSD1), 5.00 ± 0.28 μM (LSD2), >100 μM (MAO-A), >100 μM (MAO-B)[1]
In Vitro	LSD1-IN-13 (compound 7e) shows good selectivity over LSD2 (205-fold) and MAOs (>4000-fold)[1]. LSD1-IN-13 shows potent and selective antiproliferative activity in MV-4-11, with an IC_{50} of 1.36 μM[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	LSD1-IN-13 (compound 7e) (MV-4-11 xenograft mice, 0-20 mg/kg, Orally, daily for 15 days) suppresses tumor growth significantly in a dose-dependent manner[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Li C, et al. Structure-Activity Relationship Study of Indolin-5-yl-cyclopropanamine Derivatives as Selective Lysine Specific Demethylase 1 (LSD1) Inhibitors. J Med Chem. 2022 Mar 10;65(5):4335-4349.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA